Recombinant Erythropoietin as Treatment for the Late Hyporegenerative Anemia of Rh Hemolytic Disease
1 From the Divisions of Human Development and Aging and Neonatology, University of Utah School of Medicine, Salt Lake City
2 From the Department of Pediatrics, University of Utah School of Medicine, Salt Lake City
Infants with Rh hemolytic disease can develop a "late" anemia characterized by low serum concentrations of erythropoietin but erythroid progenitors that remain highly erythropoietin-responsive. Erythropoietin administration was evaluated in two patients as an alternative to transfusion. Reticulocyte counts increased after 5 days of treatment, and hematocrits increased after 10 days. Neither patient received erythrocyte transfusions following erythropoietin therapy.
Key Words: erythropoietin Rh hemolytic disease anemia neonates
Submitted on February 25, 1992
Accepted on April 10, 1992
This article has been cited by other articles:
![]() |
D. A Calhoun, S N. Murthy, B. G Bryant, S. A Luedtke, and V. Bhatt-Mehta Recent Advances in Neonatal Pharmacotherapy Ann. Pharmacother., April 1, 2006; 40(4): 710 - 719. [Abstract] [Full Text] [PDF] |
||||





